New thrombopoietin receptor agonists for platelet disorders

Drugs of Today

Volumn 48, Issue 4, 2012, Pages 293-301

  Homeida, S ^a   Ebdon, C ^a   Batty, P ^a   Jackson, B ^a   Kolade, S ^a   Bateman, C ^a   Peng, Y Y ^a   Stasi, Roberto ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Eltrombopag; Platelet disorders; Romiplostim; Thrombocytopenia; Thrombopoietin receptor agonists

Indexed keywords

ELTROMBOPAG; NEUTRALIZING ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RIBAVIRIN; ROMIPLOSTIM; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ANTIVIRAL THERAPY; BLEEDING; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; HEART INFARCTION; HEPATITIS C; HEPATITIS C RELATED THROMBOCYTOPENIA; HUMAN; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PRIMARY IMMUNE THROMBOCYTOPENIA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANIMALS; BENZOIC ACIDS; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; EVIDENCE-BASED MEDICINE; HUMANS; HYDRAZINES; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84860726902     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.4.1740505     Document Type: Review

References (30)

1. Slichter, S.J., Davis, K., Enright, H. et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005, 105(10): 4106-14. (Pubitemid 40656162)
2. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., Kuter, D.J. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98(12): 3241-8.
3. Wang, B., Nichol, J.L., Sullivan, J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004, 76(6): 628-38. (Pubitemid 39601552)
4. Roopenian, D.C., Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007, 7(9): 715-25. (Pubitemid 47327396)
5. Broudy, V.C., Lin, N.L. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004, 25(2): 52-60. (Pubitemid 38018897)
6. Erickson-Miller, C.L., DeLorme, E., Tian, S.S. et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005, 33(1): 85-93. (Pubitemid 40127647)
7. Erickson-Miller, C.L., DeLorme, E., Iskander, M. et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. Blood [46th Annu Meet Am Soc Hematol (Dec 4-7, San Diego) 2004] 2004, 104(11, Part 1): Abst 2909.
8. Erickson-Miller, C.L., Delorme, E., Tian, S.S. et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009, 27(2): 424-30.
9. Jenkins, J.M., Williams, D., Deng, Y., Uhl, J., Kitchen, V., Collins, D., Erickson-Miller, C.L. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007, 109(11): 4739-41. (Pubitemid 46827766)
10. Erhardt, J.A., Erickson-Miller, C.L., Aivado, M., Abboud, M., Pillarisetti, K., Toomey, J.R. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009, 37(9): 1030-7.
11. Siegel, R.S., Rae, J.L., Barth, S., Coleman, R.E., Reba, R.C., Kurlander, R., Rosse, W.F. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol 1989, 30(4): 206-12. (Pubitemid 19087309)
12. Louwes, H., Zeinali Lathori, O.A., Vellenga, E., de Wolf, J.T. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med 1999, 106(4): 430-4. (Pubitemid 29190596)
13. Gernsheimer, T., Stratton, J., Ballem, P.J., Slichter, S.J. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med 1989, 320(15): 974-80. (Pubitemid 19101615)
14. Hoffman, R., Zaknoen, S., Yang, H.H., Bruno, E., LoBuglio, A.F., Arrowsmith, J.B., Prchal, J.T. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N Engl J Med 1985, 312(18): 1170-4. (Pubitemid 15008034)
15. Chang, M., Nakagawa, P.A., Williams, S.A., Schwartz, M.R., Imfeld, K.L., Buzby, J.S., Nugent, D.J. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003, 102(3): 887-95. (Pubitemid 36917780)
16. Kuter, D.J., Bussel, J.B., Lyons, R.M. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008, 371(9610): 395-403. (Pubitemid 351181334)
17. Kuter, D.J., Rummel, M., Boccia, R. et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010, 363(20): 1889-99.
18. Kuter, D.J., Bussel, J.B., Newland, A. et al. Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): Final report from an open-label extension study. Blood [52nd Annu Meet Am Soc Hematol (Dec 4-7, Orlando) 2010] 2010, 116(21): Abst 68.
19. Bussel, J.B., Buchanan, G.R., Nugent, D.J. et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011, 118(1): 28-36.
20. Elalfy, M.S., Abdelmaksoud, A.A., Eltonbary, K.Y. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol 2011, 90(11): 1341-4.
21. Bussel, J.B., Provan, D., Shamsi, T. et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373(9664): 641-8.
22. Cheng, G., Saleh, M.N., Marcher, C. et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011, 377(9763): 393-402.
23. Saleh, M.N., Cheng, G., Bussel, J.B., Sun, H., Mayer, B., Bailey, C., Brainsky, A. EXTEND Study Update: Safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010. Blood [52nd Annu Meet Am Soc Hematol (Dec 4-7, Orlando) 2010] 2010, 116(21): Abst 67.
24. Stasi, R., Willis, F., Shannon, M.S., Gordon-Smith, E.C. Infectious causes of chronic immune thrombocytopenia. Hematol Oncol Clin North Am 2009, 23(6): 1275-97.
25. McHutchison, J.G., Dusheiko, G., Shiffman, M.L. et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007, 357(22): 2227-36. (Pubitemid 350190753)
26. GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia [news release]. GlaxoSmithKline, November 7, 2011. http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-721916.htm. Accessed April 4, 2012.
27. Kantarjian, H., Giles, F., List, A. et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007, 109(9): 1705-14. (Pubitemid 46668530)
28. Kantarjian, H., Fenaux, P., Sekeres, M.A. et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010, 28(3): 437-44.
29. Kantarjian, H.M., Giles, F.J., Greenberg, P.L. et al. Phase 2 study of romiplostim in patients with low- or intermediaterisk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010, 116(17): 3163-70.
30. Kuter, D.J., Mufti, G.J., Bain, B.J., Hasserjian, R.P., Davis, W., Rutstein, M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009, 114(18): 3748-56.